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Conclusions  
This study shows that Octaplex® treatment is efficient 
reversing the INR in patients taking oral VKA. In this 
population we didn’t find any difference, regarding 
overall mortality, between patients who had taken 
vitamin K plus PCC and those who had only taken PCC. 
We found a higher mortality rate in these bleeding 
patients.  
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Background 
Correcting coagulopathy has been a difficult challenge for hematologists throughout the world. Practice guidelines recommend vitamin K for the 
reversal of anticoagulation in asymptomatic patients with elevated INR, in patients who require surgery and in patients with serious bleeding. 
Prothrombin Complex Concentrate (PCC) is having progressive importance in bleeding management and reversal of International Normalized 
Ratio´s (INR) in patients taking oral vitamin K antagonists (VKA) 
Aims 
The main objective of our study is to determine the efficiency of 
PCC in the correction of INR in patients taking oral VKA and try 
to understand if the administration of vitamin K plays a role in 
the survival rates in these patients 
Methods 
We carried out a retrospective, unicenter, descriptive study that 
included 54 patients taking oral VKA that required Octaplex® 
administration in order to try to control bleeding and/or correct INR. 
Of these patients 55% were female and 45% male. Average age was 
76 years old. The data was collected from March 2011 to November 
2014. The INR results were collected before and after the treatment 
with PCC.  
Results 
87% of the studied patients (47 patients) were taking warfarin and 13% 
(7 patients) acenocoumarol. The main cause of treatment was atrial 
fibrillation. PCC was administered in 78% due to bleeding and in 22% of 
the cases to prepare patients for surgery. The mean administered doses 
were approximately 800IU. Pre-treatment INR determination was 4,4 in 
the warfarin group and 5,6 in the acenocoumarol group. In 26% of the 
patients it was not possible to have an absolute INR value (INR>10), 12 
patients in the warfarin group (26% of the group) and 1 in the 
acenocoumarol group (14% of the group). After treatment all patients 
had a measurable INR and 37% of them had an INR ≤1,5. The INR values 
dropped to 1,9 in the acenocoumarol group and to 2 in the warfarin 
group. 18 patients received concomitantly i.v. vitamin K administration. 
17 of them 10mg and one 20mg. We compared patients who only 
received PCC (33 patients) with those that received PCC and vitamin K 
(14 patients) and the impact on mortality. We excluded patients who 
did concomitant treatment with plasma (7 patients). We found a 
mortality of 36% in both groups, but we must point out their non-
uniformity. None of the patients enrolled presented reported 
thrombotic complications.  Patients presented different bleeding sites: 
23% intracranial (67% mortality), 40% gastrointestinal (38% mortality) 
and 37% other (33% mortality). The overall mortality was 37%. 
Bleeding patients presented a mortality of 43% compared with no 
bleeding that presented mortality of 21%. 
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